CTOR
CITIUS ONCOLOGY, INC.
Key Financials
Gross Profit
$5.5M
N/A
Revenue
$7.1M
N/A
Operating Income
$-23522750
↓ 14.3%
Net Income
$-24761369
↓ 17.1%
EPS (Diluted)
$-0.34
↓ 9.7%
Total Assets
$100.9M
↑ 19.6%
Shareholders' Equity
$44.9M
↓ 2.8%
Total Liabilities
$56.1M
↑ 46.7%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 9/29/2026 | View on SEC |
| ARS | 8/26/2026 | View on SEC |
| DEF 14A | 8/26/2026 | View on SEC |
| 3 | 8/14/2026 | View on SEC |
| 424B3 | 8/14/2026 | View on SEC |
| 10-Q | 8/14/2026 | View on SEC |
| 8-K | 8/14/2026 | View on SEC |
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| 8-K | 8/12/2026 | View on SEC |
| 424B3 | 8/5/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | CTOR |
| Company Name | CITIUS ONCOLOGY, INC. |
| CIK | 1851484 |
| Sector | Pharmaceutical Preparations |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 0930 |
| State of Incorporation | DE |
| Phone | (908) 967-6677 |